Health & Medicinearticle2026-11-13

Andexanet alfa versus prothrombin complex concentrate for direct anticoagulation reversal in intracranial hemorrhage: a comparative effectiveness study

Open access0 citations

Abstract

Abstract Background While guidelines recommend andexanet alfa (AA) for reversing factor Xa (FXa) inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate (4F-PCC), despite limited comparative data. This comparative effectiveness study evaluates AA vs. 4F-PCC for bleeding control in clinical practice. Methods We conducted a retrospective review of patients with acute intracranial hemorrhage who were on a factor Xa inhibitor and received 4F-PCC or AA. Demographics, clinical severity, hemorrhage volume, treatment timing, and discharge outcomes were compared. Primary outcomes were absolute and percent hemorrhage volume change, substantial hemorrhage growth (> 6 mL or >33%), and neurological deterioration (≥ 2-point GCS decrease or ≥4-point NIHSS increase). Data were analyzed using Wilcoxon Rank Sum, chi-squared tests, and Kaplan–Meier curves. Results Among 132 eligible patients, 43 received AA and 89 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Mean age was 78 years, and average baseline hemorrhage volume was 37 mL. Age, gender, race, and door-to-needle times did not differ between groups. AA patients had higher NIHSS (9 vs. 5, p = 0.003) and lower GCS (12 vs. 13, p = 0.03) scores on admission. Mean absolute and percent hemorrhage volume changes were similar; however, more patients on AA had substantial hemorrhage growth (43% vs. 22%, OR=2.65, p = 0.02). After adjustment for covariates, the association between AA and substantial hemorrhage expansion narrowly missed statistical significance (adjusted OR 2.29, P = 0.08). Neurological deterioration rates and thromboembolic complications were comparable. Conclusions AA was linked to a numerically higher risk of substantial intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, and mortality. 4F-PCC may serve as a viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.

// Source

View paper (DOI)Open access versionOpenAlexEuropean journal of medical researchPublished 2026-11-13

Authors: Hemangi Rajpal, Deepika Dilip, Audrey Huang, Jenny Yang, William Liu, Nimrod Gozum, Hannah Young, Gular Mammadli, Nicole Davis, Colleen Bond, Hasit Mehta, Stephan A. Mayer

Institutions: New York Medical College, Westchester Medical Center